Li Chenping, Chen Zhi, Shi Jiaqi, Zheng Xiuyun
Department of Pulmonary and Critical Care Medicine (PCCM), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China.
J Inflamm Res. 2024 Nov 30;17:10107-10117. doi: 10.2147/JIR.S478655. eCollection 2024.
Bacterial pneumonia is a prevalent respiratory disease and a primary cause of death among hospitalized patients. Ambroxol and loquat syrup are widely utilized pharmaceuticals for managing respiratory infections in China. This study investigates the potential application and efficacy of combining ambroxol with loquat syrup for treating bacterial pneumonia.
In this study, mice with P. aeruginosa-induced bacterial pneumonia were used to evaluate the therapeutic effects of ambroxol, loquat syrup, and their combination. A bacterial plate coating assay was performed to measure the P. aeruginosa content in saliva, lung tissue, and bronchoalveolar lavage fluid (BALF). A plate colony counting assay was conducted to assess the antibacterial activity of ambroxol and loquat syrup. Serum, BALF, and lung tissues were analyzed using qPCR, ELISA, immunohistochemistry, and hematoxylin-eosin staining to evaluate disease severity.
In this study, the experimental results demonstrate that, compared to treatment with ambroxol and/or loquat syrup alone, the combined administration of ambroxol and loquat syrup significantly increases the volume of saliva expectorated by mice infected with bacteria, concurrently augmenting bacterial presence in saliva while diminishing bacterial burden in the lungs, with significant differences observed (<0.05). Furthermore, the combined therapy of ambroxol and loquat syrup achieved better therapeutic effects on P. aeruginosa pneumonia compared to ambroxol and/or loquat syrup alone (<0.05), as evidenced by significantly reduced P. aeruginosa-induced lung injury, improved lung permeability, decreased inflammatory cell infiltration, and lower expression of inflammatory cytokines.
These findings suggest that the combination therapy of ambroxol and loquat syrup presents a safe and feasible new treatment strategy for bacterial pneumonia, offering promising benefits for ameliorating lung tissue damage and inflammation.
细菌性肺炎是一种常见的呼吸道疾病,也是住院患者死亡的主要原因。氨溴索和枇杷糖浆是中国广泛用于治疗呼吸道感染的药物。本研究探讨氨溴索与枇杷糖浆联合应用治疗细菌性肺炎的潜在应用价值和疗效。
本研究采用铜绿假单胞菌诱导的细菌性肺炎小鼠模型,评估氨溴索、枇杷糖浆及其联合用药的治疗效果。采用细菌平板涂布法测定唾液、肺组织和支气管肺泡灌洗液(BALF)中的铜绿假单胞菌含量。采用平板菌落计数法评估氨溴索和枇杷糖浆的抗菌活性。运用qPCR、ELISA、免疫组化和苏木精-伊红染色对血清、BALF和肺组织进行分析,以评估疾病严重程度。
本研究的实验结果表明,与单独使用氨溴索和/或枇杷糖浆治疗相比,氨溴索与枇杷糖浆联合给药显著增加了感染细菌小鼠咳出的唾液量,同时增加了唾液中的细菌数量,减少了肺部的细菌负荷,差异具有统计学意义(<0.05)。此外,与单独使用氨溴索和/或枇杷糖浆相比,氨溴索与枇杷糖浆联合治疗对铜绿假单胞菌肺炎具有更好的治疗效果(<0.05),表现为铜绿假单胞菌诱导的肺损伤显著减轻、肺通透性改善、炎症细胞浸润减少以及炎症细胞因子表达降低。
这些研究结果表明,氨溴索与枇杷糖浆联合治疗为细菌性肺炎提供了一种安全可行的新治疗策略,在改善肺组织损伤和炎症方面具有显著益处。